Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.66 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27997337 | 0.90 | HTR2C (0.58) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL1515134 | 0.87 | HTR2C (0.77) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL30997824 | 0.87 | HTR2C (0.77) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL7844832 | 0.84 | HTR2C (0.72) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL1515075 | 0.84 | HTR2C (0.72) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| Methyl Alcohol SCHEMBL8097139 | 0.84 | HTR2C (0.72) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL29042969 | 0.82 | HTR2C (0.60) | HTR2CDRD2ADRA1AHTR2AHTR2B | |
| SCHEMBL2095198 | 0.82 | HTR2C (0.70) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| Ammonia Solution, Strong SCHEMBL19664329 | 0.82 | HTR2C (0.70) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL3679174 | 0.81 | HTR2C (0.68) | HTR2CDRD2ADRA1AHTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | HTR2C 1450/4885DRD2 2994/4885ADRA1A 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.